• Customer Care
  • (888) 123-4567

News

At Rise Therapeutics, we are advancing oral precision immunotherapy, developing first-in-class immune modulatory drugs. Our breakthrough therapies target inflammation, autoimmunity, and cancer, offering innovative, patient-friendly solutions to transform treatment paradigms. Stay tuned for the latest updates on our clinical progress, partnerships, and scientific advancements as we push the boundaries of oral immune therapy.

Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion

 

Rockville, Maryland – September 22, 2026 – Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has completed the dose escalation portion of its ongoing Phase 1 clinical trial evaluating R-5780, the Company's lead immuno-oncology candidate. Having established a recommended dose, the study will now move into its planned dose expansion stage to enroll additional cancer patients at the highest fixed dose.

Rise Therapeutics Completes Enrollment in Four-Week Dose Expansion Cohort for the R-2487 Rheumatoid Arthritis Clinical Trial

Rockville, Maryland – June 2, 2026 – Rise Therapeutics, a clinical-stage biotechnology company advancing novel oral immunotherapies for autoimmune diseases, today announced the completion of full enrollment in the 4-week dose expansion cohort of its Phase 1b clinical trial (NCT05961592) evaluating orally dosed R-2487 in patients with active rheumatoid arthritis (RA). Confirmation of the drug free, durability of clinical response marks a key inflection point in the program’s clinical development.

Rise Therapeutics Secures New Funding to Advance First-in-Class R-2487 Oral Immune Biomodulator into Sjogren’s Disease Clinical Testing

Rockville, Maryland — September 23, 2025— Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, today announced it will be initiating clinical evaluation of R-2487 in SjD.

Rise Therapeutics Reports Ulcerative Colitis Dose Escalation Clinical Results for R-3750 at the Digestive Disease Week (DDW) Conference in San Diego May 3-6

Rockville, Maryland— April 7, 2025 — Rise Therapeutics, a biopharmaceutical company developing precision immunotherapies, today announced that it will report its first clinical results from the completed dose escalation segment of its R-3750 Phase 1 clinical trial in ulcerative colitis at the upcoming DDW conference in San Diego on May 6th.

Rise Therapeutics Receives FDA IND Clearance to Initiate Clinical Testing of R-5780 in Cancer

Rockville, Maryland – January 13, 2025 – Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a cancer Phase 1 clinical trial for its program candidate, R-5780. This is Rise Therapeutics’ fourth clinical program to enter patient clinical testing. For separate products, other clinical studies are ongoing for the treatment of ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.

Dose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials

Rockville, Maryland – January 6th, 2025 – Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has completed dose escalation enrollment stages for both its R-2487 and R-3750 clinical trials. Both studies will now initiate the planned dose expansion stages to enroll additional patients at fixed doses.